A phase II trial of reirradiation combined with pembrolizumab in patients with locoregional inoperable recurrence or second primary squamous cell carcinoma of the head and neck (HNSCC). This is an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback